Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Background Ambulatory patients receiving systemic cancer therapy are at varying risk for
venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is …

Venous thromboembolism (VTE), including deep‐vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in cancer patients. Patients with cancer …

International and national guidelines recommend low-molecular-weight heparin for the
treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …

Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in
patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim …

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with
cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental …

The association between malignancy and thrombosis has been recognized for over a
century and a half. Patients with cancer have an elevated risk of both initial and recurrent …